|Day Low/High||41.19 / 42.78|
|52 Wk Low/High||11.30 / 45.85|
- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks
- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability
- Jerold Chun, M.D., Ph.D. (Sanford Burnham Prebys), and Eric Gershwin, M.D. (UC Davis Health), to Present
In recent trading, shares of Arena Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties
Data Readout Expected in Q1 2018
Significant improvement in pulmonary vascular resistance (PVR) with ralinepag compared to placebo
Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.
Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.
Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.
The company just beat a bench mark, previously set by Johnson & Johnson.
Jim Cramer is bullish on Xilinx, Arena Pharmaceuticals, Magellan Midstream, Altria and Bank of Montreal.
Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.